• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Perrigo Company plc

    6/26/25 2:33:44 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    11-K 1 a202411-k.htm 11-K Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 11-K

    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    (Mark One)

    [X]    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended: December 31, 2024

    OR

    [ ]    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from ________ to ________

    Commission file number 001-36353

    A.Full title of the plan and the address of the plan, if different from that of the issuer named below:

    Perrigo Company Profit-Sharing and Investment Plan
    515 Eastern Avenue
    Allegan, MI 49010

    B.Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    Perrigo Company plc
    The Sharp Building
    Hogan Place
    Dublin 2, Ireland


















    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN



    Table of Contents

    Page
    Report of Independent Registered Public Accounting Firm
    3
    Financial Statements
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    4
    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2024
    5
    Notes to Financial Statements
    6
    Supplemental Schedules
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2024
    12
    Exhibit Index
    13



    2


    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    Perrigo Company Retirement Committee
    Perrigo Company Profit-Sharing and Investment Plan
    Allegan, MI


    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of the Perrigo Company Profit-Sharing and Investment Plan (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes and schedule (collectively referred to as the financial statements).

    In our opinion, these financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.


    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits of the financial statements provide a reasonable basis for our opinion.


    Supplemental Information

    The accompanying December 31, 2024 supplemental schedule of assets (held at end of year) has been subjected to audit procedures performed in conjunction with our audit of the 2024 Perrigo Company Profit-Sharing and Investment Plan financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in relation to the financial statements as a whole.

    /s/ Rehmann Robson
    REHMANN ROBSON LLC


    We have served as Perrigo Company Profit-Sharing and Investment Plan’s independent auditor since 2022.

    Grand Rapids, Michigan
    June 26, 2025
    3

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
    December 31,
    20242023
    Assets
    Total investments, at fair value$1,018,298,119 $959,498,991 
    Receivables:
    Employer contributions13,190,124 13,969,255 
    Notes receivable from participants9,666,277 9,856,684 
    Total receivables22,856,401 23,825,939 
    Net assets available for benefits $1,041,154,520 $983,324,930 



    The accompanying notes are an integral part of these financial statements.





    4

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
    Year Ended
    December 31, 2024
    Additions to net assets attributed to
    Contributions:
    Participant$36,396,790 
    Rollover2,625,727 
    Employer25,367,761 
    Total contributions64,390,278 
    Interest on notes receivable from participants745,489 
    Investment income:
    Net appreciation in fair value of investments110,691,742 
    Interest, dividends and other16,265,661 
    Total Additions192,093,170 
    Deductions
    Distribution of benefits to participants133,863,341 
    Administrative fees400,239 
    Total Deductions134,263,580 
    Net Increase57,829,590 
    Net Assets Available for Benefits, beginning of year983,324,930 
    Net Assets Available for Benefits, end of year$1,041,154,520 



    The accompanying notes are an integral part of these financial statements.


    5

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________


    1.    Plan Description

    The following description of the Perrigo Company Profit-Sharing and Investment Plan (the "Plan") provides only general information. Participants should refer to the Plan document or Plan summary for a more complete description of the Plan's provisions.

    General

    The Plan Sponsor is Perrigo Company plc. The Plan is a defined contribution plan in which substantially all U.S. employees of Perrigo Company plc and certain of its domestic related companies (collectively, the "Company" or "Employer") are eligible to participate. Employees are allowed the option to roll over assets from other plans into the Perrigo Company Profit-Sharing and Investment Plan once they have met the eligibility requirements. The Company's Retirement Plan Committee is responsible for the oversight of the Plan and the appropriateness of the Plan's investment offerings and monitors investment performance.

    The minimum term of service for employees to participate in the elective deferral and matching contribution components of the Plan is one month of service, which means a consecutive 30-day period of employment beginning with the employee's date of hire. There is no minimum term of service for employees to participate in the Employer nonelective and discretionary contribution components of the Plan. Plan entry dates are at the beginning of each payroll period after the minimum term requirements (if applicable) are satisfied.

    The Plan has an automatic enrollment feature for new hires that begins with an initial pre-tax contribution rate of 4% of a participant's eligible compensation, as defined in the Plan document, and is invested in the Plan's Qualified Default Investment Alternative, unless the participant has affirmatively elected another investment from among the Plan's investment options. Automatic enrollment occurs on or around the date that the employee becomes eligible to participate, as defined above. The automatic enrollment percentage increases annually by 1% up to a maximum deferral percentage of 10%. Prior to automatic enrollment and at any other time, employees may elect to opt out from participating in the Plan, or they may elect to defer more or less than the 4% automatic elective deferral as well as choose their own investment allocations offered by the Plan.

    The Plan conforms to the safe harbor provisions of Sections 401(k) and 401(m) of the Internal Revenue Code ("IRC"). The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). The Plan is administered by the Retirement Plan Committee (the "Committee").

    Contributions

    A participant may elect to defer, in whole percentages, an amount between 1% and 50% of eligible compensation, not to exceed Internal Revenue Service ("IRS") limitations for the Plan year. The total IRS limit was $23,000 for the 2024 Plan year. In addition, participants who are at least 50 years of age by the end of a Plan year may elect to make an additional "catch up" contribution, not to exceed the IRS limit of $7,500 for the 2024 Plan year. Participants may also make a Roth contribution on an after-tax basis. Additionally, participants may make contributions to a traditional after-tax source between 1% and 4% of eligible compensation.

    Effective January 1, 2017, participants are no longer permitted to invest more than 20% of their total account balance in the Perrigo Company Stock Fund, which holds the Perrigo Company plc ordinary shares.

    •If more than 20% of a participant's account was invested in the Perrigo Company Stock Fund as of January 1, 2017, the amount in excess of the 20% limit was grandfathered in and allowed to remain invested in the Perrigo Company Stock Fund.

    •Upon initial enrollment in the Plan, participants may direct no more than 20% of their account to be invested in the Perrigo Company Stock Fund.

    6

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________


    •Future allocation changes and exchanges into the Perrigo Company Stock Fund are limited to 20% of each participant's account.

    •Rollovers are not permitted directly into the Perrigo Company Stock Fund.

    •Any future contributions and/or loan repayments that would exceed the Plan's 20% limit on investment to the Perrigo Company Stock Fund will be redirected to the Plan's Qualified Default Investment Alternative, which is the Vanguard Target Retirement Income Trust I as of December 31, 2024.

    The Company matches pre-tax and Roth employee contributions per Plan year at the rate of 100% of the first 2% of employee contributions and 50% of the next 2% of employee contributions. Matching contributions are effective upon meeting the 30-day service requirement and participation in the Plan. The Company has the right under the Plan to reduce or suspend such contributions at any time. After-tax contributions are not eligible for a Company match.

    In accordance with the safe harbor provisions, the Plan includes an annual Employer nonelective contribution of 3% of an employee's eligible compensation, as defined in the Plan document. In addition, the Company may make a discretionary contribution at the option of the Board of Directors of Perrigo Company plc. Employees are eligible as of their date of hire to receive both the Employer nonelective and discretionary contributions, which are deposited in the eligible employee's investment account after the end of each Plan year. The Employer nonelective and discretionary contribution amounts approved for the 2024 Plan year were $12,989,447, which are included in the employer contribution receivable on the statement of net assets available for benefits as of December 31, 2024.

    Participant contributions are recorded when withheld from compensation. Employer contributions are recorded in the period in which they become obligations of the Company.

    Participant Accounts

    Each participant's account is credited with the participant's contributions, allocations of Employer matching, Employer discretionary and nonelective profit-sharing contributions, and Plan earnings. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. Allocations are based on participant compensation, account balances or specific participant transactions, as defined. As of December 31, 2024, the Plan offers various investment options, including mutual funds, common collective trusts, a money market fund, and Perrigo Company plc ordinary shares, for Plan participants. Participants elect which of these investment options meet their risk and return objectives.

    Vesting

    Amounts credited to a participant's investment account relating to participant contributions and Employer matching and nonelective profit-sharing contributions are 100% vested at all times.

    Notes Receivable from Participants

    Participants may borrow from their investment accounts, as defined in the Plan document, a minimum of $1,000 up to a maximum equal to the lesser of $50,000 or 50% of their account balance. The loans are secured by an equivalent amount in the remaining portion of the participant's accounts. All loans must be repaid within five years, except for loans used to acquire or rehabilitate a principal residence, which must be repaid within 10 years. Interest rates range from 4.25% to 9.50% on outstanding loans at December 31, 2024. The loans are repaid ratably through payroll deductions. Participant loans are valued at their unpaid principal balance plus any accrued but unpaid interest. The interest earned on participant loans is allocated to the respective funds in accordance with participant elections.

    7

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________


    Withdrawals

    Subject to certain restrictions as set forth in the Plan document, a participant may make a hardship withdrawal from his or her account balance during employment. This hardship withdrawal is subject to a 10% federal income tax penalty if the participant is below the age of 591/2. A participant may also elect to make a withdrawal, provided that the participant has reached 591/2 years of age, even if the participant is still employed. Other in-service withdrawal rights include the ability to withdraw rollover contributions, after-tax contributions, and elective transfer contributions at any time, as well as the right to request a qualified reservist distribution or a deemed severance withdrawal under the Heroes Earnings Assistance and Relief Tax Act of 2008 (the HEART Act).

    Payment of Benefits

    Upon termination of service, participants may elect to receive a lump-sum amount equal to the value of their vested account, installments or a partial payment. Participants may also elect to roll over their account balance into another qualified retirement plan, or postpone distributions until such time they are required. If no action is taken at the time of separation, vested account balances of $1,000 or less are distributed to the participant, and vested account balances between $1,000 and $5,000 are rolled into an IRA established for the participant.

    Forfeitures

    There were no forfeited non-vested amounts in the 2024 or 2023 Plan years.

    Administrative Expenses

    The Company pays the administrative costs of the Plan associated with any professional services provided to the Plan and the cost of communications to the participants. Administrative expenses, such as loan administration and some withdrawal fees, are deducted directly from the participants' accounts.

    Concentration of Investments

    Investments at December 31, 2024 and 2023 included Perrigo Company plc ordinary shares amounting to 312,694 shares totaling $8,039,371 and 333,556 shares totaling $10,733,830, respectively. This investment represented approximately 1% of total investments at December 31, 2024 and 2023. The quoted market value of Perrigo Company plc ordinary shares decreased by 20% from December 31, 2023 to December 31, 2024.

    Risks and Uncertainties

    Participants in the Plan invest in various investment securities. Investment securities, including Perrigo Company plc ordinary shares, are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the financial statements.

    2.    Summary of Significant Accounting Policies

    Basis of Accounting

    The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").
    8

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________



    Use of Estimates

    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of net assets and changes therein. Actual results could differ from those estimates.

    Investment Valuation and Income Recognition

    Investment purchases and sales are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Capital gain distributions are included in dividend income. Net change includes the Plan's gains and losses on investments bought and sold as well as held during the year. The Plan's investments are stated at fair value. See Note 4 for a discussion of fair value measurements.

    Payment of Benefits

    Distributions of benefits are recorded when paid.

    3.    Assets in Trust Fund

    Vanguard Fiduciary Trust Company ("Vanguard") is the Plan's Trustee. The Trustee manages the trust fund on behalf of the Plan. The Trustee has no discretionary investment authority over the investment options made available to participants under the Plan, including the investments in Perrigo Company plc ordinary shares. Each participant is entitled to exercise voting rights attributable to the Perrigo Company plc ordinary shares allocated to his or her account and is notified by the Trustee prior to the time such rights are to be exercised. The Trustee is not permitted to vote any allocated shares for which instructions have not been given by a participant. The Trustee is required, however, to vote any unallocated shares on behalf of the collective best interest of Plan participants and beneficiaries.

    4.    Investments

    The Plan's investments are stated at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

    Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset. The Plan utilizes a fair value hierarchy for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The three levels of the fair value hierarchy are described as follows:

    Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets in active markets.

    Level 2 - Inputs to the valuation methodology include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in inactive markets, other inputs that are observable or can be corroborated by observable market data.

    Level 3 - Inputs to the valuation methodology are both significant to the fair value measurement and unobservable.

    The following valuation methodologies were used to measure the fair value of the Plan's investments:

    Mutual funds and money market fund: Valued at quoted market prices on an exchange and in active markets, which represent the net asset values (“NAV”) of shares held by the Plan. Mutual funds held by the
    9

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________


    Plan are open-ended mutual funds that are registered with the SEC. Shares held in money market funds are comprised of debt securities that are structured to maintain a value of $1 per share.

    Common collective trusts: Valued based on the published year-end unit NAV. Unit values are determined by the issuer or third party administrator by dividing the fair values of the total net assets at year-end by the outstanding units. Were the Plan to initiate a significant redemption of the collective trust, a notification period is required and investment advisers may reserve the right to temporarily delay withdrawal from the trust in order to ensure the securities liquidations will be carried out in an orderly business manner. The funds held by the Plan have no unfunded commitments or notice period requirement for participants.

    Perrigo Company plc ordinary shares: Valued at the closing price reported on the active market on which the security is traded.

    The Plan's valuation methods may result in a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Although Plan management believes the valuation methods are appropriate and consistent with the market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    The tables below set forth by level within the fair value hierarchy the Plan's investments.

    December 31, 2024Level 1Level 2Total
    Mutual funds$321,739,845 $— $321,739,845 
    Common collective trusts— 645,420,589 645,420,589 
    Perrigo Company plc ordinary shares8,039,371 — 8,039,371 
    Money market fund43,098,314 — 43,098,314 
    Investments, at fair value$372,877,530 $645,420,589 $1,018,298,119 


    December 31, 2023Level 1Level 2Total
    Mutual funds$399,636,893 $— $399,636,893 
    Common collective trusts— 504,701,370 504,701,370 
    Perrigo Company plc ordinary shares10,733,830 — 10,733,830 
    Money market fund44,426,898 — 44,426,898 
    Investments, at fair value$454,797,621 $504,701,370 $959,498,991 


    The availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. Plan management evaluates the significance of transfers between levels based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits.

    There were no transfers between Level 1, 2, and 3 investments during the 2024 and 2023 Plan years.

    5.    Related Party Transactions

    The trustee of the Plan, Vanguard, manages investments in its sponsored funds and, therefore, is deemed a party-in-interest and a related party. Fees paid to Vanguard were $400,239 in 2024, including $30,750 of loan origination fees collected on behalf of participants. The Plan also invests in Perrigo Company plc ordinary shares, therefore these transactions qualify as party-in-interest transactions. Cash dividends of $351,886 were paid to the Plan by the Company during 2024 related to shares held by the Plan on the dividend
    10

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN
    NOTES TO FINANCIAL STATEMENTS
    ______________________________________________________________________________________________________


    record dates. These dividends are included in Interest, dividends and other in the Statement of Changes in Net Assets Available for Benefits.

    6.    Plan Termination

    Although the Company has not expressed any intent to do so, it has the right to reduce or suspend contributions at any time and to terminate the Plan, subject to the provisions of ERISA.

    7.    Income Tax Status

    Effective January 1, 2021, the Plan was amended and restated on a volume submitter plan document sponsored by Vanguard. Vanguard received an advisory letter from the IRS, dated June 30, 2020, which states that the volume submitter document satisfies the applicable provisions of the IRC. The Plan itself has not received a determination letter from the IRS. However, the Committee and the Plan’s tax counsel believe that the Plan is currently designed and being operated in compliance with the applicable requirements of the IRC, and therefore believe the Plan is qualified and the related trust is tax-exempt. Therefore, no provision for income taxes has been included in the Plan’s financial statements.

    Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. As of December 31, 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.


    11

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    December 31, 2024
    EIN: 38-2799573
    Plan Number: 003
    (a)(b)
    Identity of Issue, Borrower, Lessor or Similar Party
    (c)
    Description of Investment, including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value
    (d)
    Cost
    (e)
    Current
    Value
    Money market fund
    *Vanguard Federal Money Market Fund43,098,314  shares**$43,098,314 
    Mutual funds
    Baird Core Plus Bond Fund; Institutional Class2,975,055  shares**29,780,300 
    MFS Int'l Growth Fund; Class R6264,539  shares**10,949,276 
    Neuberger Berman Genesis Fund; Class R6449,331  shares**29,363,754 
    *Vanguard Equity Income Fund Admiral Shares646,617  shares**57,012,225 
    *Vanguard Extended Market Index Fund: Inst'l Shares187,309  shares**26,985,599 
    *Vanguard Inflation-Protected Securities Fund; Inst'l Shares701,173  shares**6,429,756 
    *Vanguard Institutional Index Fund Inst'l Plus Shares226,962  shares**108,687,395 
    *Vanguard Total Bond Market Index Fund; Inst'l Shares2,406,490  shares**22,813,527 
    *Vanguard Total International Stock Index Fund; Inst'l Shares215,070  shares**27,253,652 
    American Funds Capital World Bond Fund; Class R6157,770  shares**2,464,361 
    Total mutual funds321,739,845 
    Common collective trusts
    Harbor Capital Appreciation CIT; Class 44,937,621  shares**87,889,656 
    Schroder International Multi-Cap Equity Trust; Class 11,059,017  shares**16,859,553 
    *Vanguard Target Retirement 2020 Trust I151,229  shares**11,437,413 
    *Vanguard Target Retirement 2025 Trust I542,682  shares**43,544,828 
    *Vanguard Target Retirement 2030 Trust I995,463  shares**83,768,246 
    *Vanguard Target Retirement 2035 Trust I1,181,485  shares**105,612,948 
    *Vanguard Target Retirement 2040 Trust I846,711  shares**81,081,022 
    *Vanguard Target Retirement 2045 Trust I788,809  shares**78,683,723 
    *Vanguard Target Retirement 2050 Trust I606,534  shares**61,787,660 
    *Vanguard Target Retirement 2055 Trust I339,244  shares**42,134,070 
    *Vanguard Target Retirement 2060 Trust I283,472  shares**18,502,232 
    *Vanguard Target Retirement 2065 Trust I197,370  shares**7,924,407 
    *Vanguard Target Retirement 2070 Trust I39,432  shares**965,294 
    *Vanguard Target Retirement Income Trust I76,939  shares**5,229,537 
    Total common collective trusts645,420,589 
    Common stock
    *Perrigo Company plc ordinary shares312,694  shares**8,039,371 
    Total investments1,018,298,119 
    *Participant loans***
    Various maturity dates, with interest rates ranging from 4.25% to 9.50%; collateralized by participant account balances
    —9,666,277 
    Total$1,027,964,396 

    * A party-in-interest as defined by ERISA.
    ** The cost of participant-directed investments is not required to be disclosed.
    *** Inclusive of outstanding deemed distributions.
    12

    PERRIGO COMPANY PROFIT-SHARING AND INVESTMENT PLAN


    EXHIBIT INDEX

    Exhibit Number    Description    

    23.1    Consent of Independent Registered Public Accounting Firm






    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

    Perrigo Company Profit-Sharing and Investment Plan
    (Name of Plan)
    DateJune 26, 2025/s/ Eduardo Bezerra
    Eduardo Bezerra
    Chief Financial Officer
    Perrigo Company plc
    13
    Get the next $PRGO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parker Geoffrey M. bought $94,850 worth of Ordinary Shares (3,500 units at $27.10), increasing direct ownership by 17% to 23,762 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/14/25 2:06:42 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Svend bought $27,900 worth of Ordinary Shares (1,000 units at $27.90), increasing direct ownership by 0.99% to 101,853 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/31/24 5:04:45 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison exercised 1,698 units of Ordinary Shares at a strike of $27.26, covered exercise/tax liability with 1,262 units of Ordinary Shares and bought $67,877 worth of Ordinary Shares (2,490 units at $27.26), increasing direct ownership by 24% to 15,372 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:58:50 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and President of CSCI Khoury Roberto

      4 - PERRIGO Co plc (0001585364) (Issuer)

      7/10/25 11:41:30 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Alford Bradley A

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:22:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parker Geoffrey M.

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:18:53 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance

      Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & Chief Commercial Officer to Lead Global Market Activation Triona Schmelter, EVP & President Consumer Self-Care Americas (CSCA), to Leave Organization DUBLIN, July 1, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that it is scaling and optimizing its proven growth model—anchored in global Category Leadership and Market Activation—across the organization to enhance agility, accelerate innovation, and drive long-term sustainabl

      7/1/25 4:30:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Good Start® | Dr. Brown's™ Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby

      Beginning July 1, 2025, a month-long giveaway contest will award 100 winners with two months' worth of Good Start® | Dr. Brown's™ Gentle Pro™ baby formula plus Dr. Brown's products (valued at $516.49) – and support families in need with a donation of formula to Baby2Baby that exceeds the total contest value GRAND RAPIDS, Mich., July 1, 2025 /PRNewswire/ -- Today, the makers of Good Start® | Dr. Brown's™ infant formula announced a nationwide giveaway contest to support families across the country. Beginning July 1st, the makers of Good Start® | Dr. Brown's™ will launch a month-long contest giving consumers the chance to win up to 500 bottles' worth of Good Start® | Dr. Brown's™ Gentle Pro™ fo

      7/1/25 9:02:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Global Operations and Supply Chain Leadership Transition

      Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

      6/4/25 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

      For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

      7/13/23 8:32:15 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    SEC Filings

    See more
    • Perrigo Company plc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - PERRIGO Co plc (0001585364) (Filer)

      7/1/25 5:22:36 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Perrigo Company plc

      11-K - PERRIGO Co plc (0001585364) (Filer)

      6/26/25 2:33:44 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

      SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

      6/6/25 12:00:06 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Perrigo downgraded by Argus

      Argus downgraded Perrigo from Buy to Hold

      1/14/25 8:38:48 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

      1/6/25 8:24:36 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Perrigo with a new price target

      Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously

      9/24/24 8:23:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Financials

    Live finance-specific insights

    See more
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      10/31/24 11:55:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      2/13/24 1:05:29 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

      SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

      1/24/24 2:27:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perrigo Announces Global Operations and Supply Chain Leadership Transition

      Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

      6/4/25 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

      Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

      1/6/25 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

      Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

      9/4/24 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care